1497436-02-8

Basic information

• Product Name: (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid
• CAS NO: 1497436-02-8
• Molecular Weight: 390.85
• Mol File: 1497436-02-8.mol

Chemical Properties

• CAS DataBase Reference: (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid(1497436-02-8)
• EPA Substance Registry System: (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylic acid(1497436-02-8)

Safety Data

• Hazardous Substances Data: 1497436-02-8(Hazardous Substances Data)

Upstream product

• 1497435-99-0 ethyl (2E)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxylate 
• 1780-26-3 2,4-dichloro-2-methylpyrimidine 
• 1202357-66-1 ethyl 2-[(6-chloro-2-methylpyrimidin-4-yl)amino]-1,3-thiazole-5-carboxylate 

Downstream Products

• 1497436-07-3 (2E)-N-(2-chloro-6-methylphenyl)-2-[(6-chloro-2-methylpyrimidin-4-yl)imino]-3-(4-methoxybenzyl)-2,3-dihydro-1,3-thiazole-5-carboxamide 
• 1497436-11-9 (2E)-N-(2-chloro-6-methylphenyl)-3-(4-methoxybenzyl)-2-[(2-methyl-6-piperazin-1-ylpyrimidin-4-yl)imino]-2,3-dihydro-1,3-thiazole-5-carboxamide 
• 1497436-15-3 C₃₀H₃₀⁽²⁾H₄ClN₇O₃S 
• 1497436-18-6 C₄₁H₄₉⁽²⁾H₄ClN₈O₆S 

Relevant articles and documents

Synthesis and biopharmaceutical studies of jltn as potential dasatinib prodrug

Dasatinib was identified as a potent orally administered Src/Abl kinase inhibitor with excellent antiproliferative activity against Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. The low bioavailability of Dasatinib may be due to both incomplete oral absorption and first-pass metabolism. A prodrug, JLTN, was synthesized to minimize the first-pass effect of Dasatinib and improve the oral bioavailability following oral administration via targeting intestinal peptide transporter and enhancing chemical stability. Biological evaluation data indicated that there was a 150%-fold increase in oral bioavailability of this prodrug compared to the parent drug Dasatinib in monkeys.